Combining Immune and Gene Therapy For 2 Rare Diseases

Post Date: 
20 July 2016

Selecta Biosciences is assisting in the development of gene therapies for Methylmalonic Acidemia (MMA) and Ornithine Transcarbamylase Deficiency (OTC) — 2 rare genetic disorders of metabolism.
 Selecta’s SVP-Rapamycin (SEL-110) immune therapy attenuates the development of antibodies against gene therapy, thereby allowing for multiple injections of gene therapy to be administered.The 2 programs that will combine SVP-Rapamycin with a specific gene therapy are the Methylmalonic Acidemia (MMA) Program and the Ornithine Transcarbamylase (OTC) Deficiency Program.

Read more here